Work of breathing, not dysoxia, as the cause of low central venous blood O2 saturation in sepsis

The review by Nguyen et al. [1] acknowledges the substantially lower baseline central venous oxygen saturation (ScvO2) values reported by Rivers et al. [2] (48.6 ± 11.2 %) when compared to those for ProCESS [3] (71 ± 13 %), ARISE [4] (72.7 ± 10.5 %) and ProMISe [5] (64 ± 20 %) trials. Assuming normality, the distribution of baseline ScvO2 values in the study by Rivers et al. differed from those of the other trials (Fig. 1; p < 0.0001 by t test). Nguyen et al. ascribed this difference to “earlier central venous catheter (CVC) placement, greater shock severity or imbalances between O2 delivery and O2 consumption before corrective interventions”.

Work of breathing, not dysoxia, as the cause of low central venous blood O 2 saturation in sepsis

Guillermo Gutierrez
The review by Nguyen et al. [1] acknowledges the substantially lower baseline central venous oxygen saturation (S cv O 2 ) values reported by Rivers et al. [2] (48.6 ± 11.2 %) when compared to those for ProCESS [3] (71 ± 13 %), ARISE [4] (72.7 ± 10.5 %) and ProMISe [5] (64 ± 20 %) trials. Assuming normality, the distribution of baseline S cv O 2 values in the study by Rivers et al. differed from those of the other trials ( Fig. 1; p < 0.0001 by t test). Nguyen et al. ascribed this difference to "earlier central venous catheter (CVC) placement, greater shock severity or imbalances between O 2 delivery and O 2 consumption before corrective interventions".
One aspect of these trials that has been ignored up to now is the CVC position in the superior vena cava. According to accepted guidelines, the tip of the CVC should lie below the anterior first rib and above the right atrium, placing the tip of the CVC below the opening of the azygos vein, a vessel carrying venous blood from the intercostal muscles and portions of the diaphragm.
In the study by Rivers et al., 53.8 % of patients randomized to the early goal-directed therapy (EGDT) group required invasive mechanical ventilation during the first 6 h of treatment, a greater rate (p < 0.0001; Chi Square test) than those reported by ProCESS (26.4 %), ARISE (22.2 %), and ProMISe (19 %). Furthermore, the baseline respiratory rate for the EGDT cohort in Rivers et al. (31.8 ± 10.8 bpm) was greater (p < 0.001) than those reported by ProCESS (25.4 ± 7.0 bpm) and ARISE (24. ± 7.5 bpm). The baseline respiratory rate for patients in the ProMISe trial was not reported.
These data infer that patients in the study of Rivers et al. experienced considerable respiratory distress prior to the initiation of mechanical ventilation. This condition was likely associated with an increased work of breathing and the discharge of highly desaturated blood by the azygos vein into the superior vena cava, in close proximity to the fiber optic lumen of the catheter tip, precisely where S cv O 2 was measured spectrophotometrically.
It is reasonable, therefore, to propose that the low S cv O 2 values reported in the study of Rivers et al. reflected work by the muscles of respiration and not sepsis-associated systemic tissue dysoxia. In that instance, the S cv O 2 increases observed during the first 6 h of treatment in the study by Rivers et al. may have been in response to unloading of respiratory muscles by mechanical ventilation and not to red blood cell transfusion or dobutamine infusion as proposed by their treatment algorithm.   [2], ProCESS [3], ARISE [4] and ProMISe trials [5]. Baseline S CV O 2 was substantially lower in the Rivers et al trial when compared to each of the other trials (p < 0.0001)